Bausch Health Companies (SWX:VRX) - Stock Price, News & Analysis

VRX Stock Overview

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally.

About the company

VRX fundamental analysis
Snowflake Score
Valuation	5/6
Future Growth	3/6
Past Performance	0/6
Financial Health	2/6
Dividends	0/6

Rewards

Risk Analysis

Negative shareholders equity

Bausch Health Companies Inc. Competitors

Dottikon ES Holding

SWX:DESN

CHF3.2b

Sandoz Group

SWX:SDZ

CHF13.2b

Cosmo Pharmaceuticals

SWX:COPN

CHF1.2b

Newron Pharmaceuticals

SWX:NWRN

CHF130.4m

Price History & Performance

Summary of all time highs, changes and price drops for Bausch Health Companies
Historical stock prices
Current Share Price	US$24.11
52 Week High	US$0
52 Week Low	US$0
Beta	0.86
1 Month Change	0%
3 Month Change	0%
1 Year Change	0%
3 Year Change	0%
5 Year Change	2.20%
Change since IPO	-81.27%

Recent updates

Shareholder Returns

	VRX	CH Pharmaceuticals	CH Market
7D	0%	3.2%	0.03%
1Y	0%	-11.8%	-3.3%

Price Volatility

Is VRX's price volatile compared to industry and market?
VRX volatility
VRX Average Weekly Movement	0%
Pharmaceuticals Industry Average Movement	3.3%
Market Average Movement	3.5%
10% most volatile stocks in CH Market	7.5%
10% least volatile stocks in CH Market	2.0%

Stable Share Price: VRX has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine VRX's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
n/a	20,270	Tom Appio	www.bauschhealth.com

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb.

Bausch Health Companies Inc. Fundamentals Summary

How do Bausch Health Companies's earnings and revenue compare to its market cap?
VRX fundamental statistics
Market cap	CHF2.86b
Earnings (TTM)	-CHF540.08m
Revenue (TTM)	CHF7.99b

0.4x

P/S Ratio

-5.3x

P/E Ratio

Is VRX overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
VRX income statement (TTM)
Revenue	US$8.76b
Cost of Revenue	US$2.56b
Gross Profit	US$6.20b
Other Expenses	US$6.79b
Earnings	-US$592.00m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

May 02, 2024

Earnings per share (EPS)	-1.61
Gross Margin	70.78%
Net Profit Margin	-6.76%
Debt/Equity Ratio	-27,302.4%

How did VRX perform over the long term?

See historical performance and comparison

VRX Stock Overview

Rewards

Risk Analysis

Bausch Health Companies Inc. Competitors

SWX:DESN

CHF3.2b

SWX:SDZ

CHF13.2b

SWX:COPN

CHF1.2b

SWX:NWRN

CHF130.4m

Price History & Performance

Recent News & Updates

Bausch Health, Canada Inc. Announces Acne Vulgaris Treatment PrARAZLO(TM) (Tazarotene Lotion, 0.045%) Now Available to Patients Through British Columbia PharmaCare Public Drug Plan

Bausch Health Companies Inc. to Report Q1, 2024 Results on May 02, 2024

Bausch Health, Canada Inc. Announces First Public Drug Plan Listings for (Pr)UCERIS(R) (budesonide) Aerosol Foam to Help Address the Unmet Need for the Treatment of Mild to Moderate Distal Ulcerative Colitis in Adults

Insufficient new directors

Bausch Health Companies Inc. and Salix Pharmaceuticals Announces Phase 2 Investigator-Initiated Study of RELISTOR in Patients with Resectable Head and Neck Squamous Cell Carcinoma

Full year 2023 earnings released: US$1.62 loss per share (vs US$0.62 loss in FY 2022)

Recent updates

Bausch Health, Canada Inc. Announces Acne Vulgaris Treatment PrARAZLO(TM) (Tazarotene Lotion, 0.045%) Now Available to Patients Through British Columbia PharmaCare Public Drug Plan

Bausch Health Companies Inc. to Report Q1, 2024 Results on May 02, 2024

Bausch Health, Canada Inc. Announces First Public Drug Plan Listings for (Pr)UCERIS(R) (budesonide) Aerosol Foam to Help Address the Unmet Need for the Treatment of Mild to Moderate Distal Ulcerative Colitis in Adults

Insufficient new directors

Bausch Health Companies Inc. and Salix Pharmaceuticals Announces Phase 2 Investigator-Initiated Study of RELISTOR in Patients with Resectable Head and Neck Squamous Cell Carcinoma

Full year 2023 earnings released: US$1.62 loss per share (vs US$0.62 loss in FY 2022)

Bausch Health Companies Inc., Annual General Meeting, May 14, 2024

Bausch Health Companies Inc. to Report Q4, 2023 Results on Feb 22, 2024

Bausch Health Companies Inc. Announces the U.S. Launch of CABTREO Topical Gel

Bausch Health Companies Inc. and Salix Pharmaceuticals Ltd. Provides Update on Court of Appeals for the Federal Circuit Hears Oral Arguments on Patent Dispute

Bausch Health Companies Inc. Announces Positive Topline Results from Global Phase 2 Study Evaluating Amiselimod (An S1p Antagonist) to Treat Ulcerative Colitis

Bausch Health, Canada Announces DUOBRII Lotion to Treat Moderate to Severe Plaque Psoriasis Now Available Through Quebec's Public Drug Plan

New minor risk - Profitability

No longer forecast to breakeven

Third quarter 2023 earnings released: US$1.04 loss per share (vs US$1.10 profit in 3Q 2022)

FDA Approves Bausch Health Companies Inc. and Its Dermatology Business, Ortho Dermatologics's Cabtreo Topical Gel for the Treatment of Acne Vulgaris in Patients Twelve Years of Age and Older

Bausch Health Companies Inc. to Report Q3, 2023 Results on Nov 02, 2023

Bausch Health Companies Inc. Announces Executive Changes

Bausch Health Companies Inc. Announces New Treatment PrUCERIS (Budesonide) Aerosol Foam Now Available Across Canada to Treat Mild to Moderate Distal Ulcerative Colitis in Adults

Bernstein Liebhard LLP Files A Securities Class Action Lawsuit Against Bausch Health Companies Inc

Bernstein Liebhard LLP Files A Securities Class Action Lawsuit Against Bausch Health Companies Inc

Bausch Health Companies Inc. Raises Earnings Guidance for the Fiscal Year 2023

Second quarter 2023 earnings released: EPS: US$0.072 (vs US$0.40 loss in 2Q 2022)

Levi & Korsinsky, LLP Files Complaint to Recover Losses Suffered by Purchasers of Bausch Health Companies Inc

Bausch Health Companies Inc. to Report Q2, 2023 Results on Aug 03, 2023

New major risk - Financial position

No longer forecast to breakeven

Forecast to breakeven in 2025

First quarter 2023 earnings released: US$0.56 loss per share (vs US$0.19 loss in 1Q 2022)

Bausch Health Companies Inc. Provides Consolidated Earnings Guidance for the Full Year 2023

Forecast breakeven date pushed back to 2025

Full year 2022 earnings released: US$0.62 loss per share (vs US$2.64 loss in FY 2021)

Bausch Health Companies Inc. to Report Q4, 2022 Results on Feb 23, 2023

Bausch Health Companies Inc. Announces Availability of ARAZLOTM

Third quarter 2022 earnings released: EPS: US$1.10 (vs US$0.52 in 3Q 2021)

Bausch Health Companies Inc. Revises Consolidated Earnings Guidance for the Full Year 2022

Bausch Health Companies Inc. to Report Q3, 2022 Results on Nov 03, 2022

Bausch Health Companies Inc. and Glenmark Specialty S.A. Announce the Approval of RYALTRIS® in Canada

Insider recently sold CHF681k worth of stock

Bausch Health Companies Inc.(TSX:BHC) dropped from FTSE All-World Index (USD)

Bausch Health Companies Inc. Responds to Norwich Pharmaceuticals Tentative FDA Approval for 200 mg Rifaximin

Bausch Health Companies Inc. to Appeal XIFAXAN® Patent Decision to U.S. Court of Appeals for the Federal Circuit

Second quarter 2022 earnings released

Bausch Health Companies Inc. Announces Unaudited Impairment Results for the Quarter Ended June 30, 2022

Insufficient new directors

Bausch Health Companies Inc. to Report Q2, 2022 Results on Aug 09, 2022

Insufficient new directors

Bausch Health Companies Inc. Announces Updates to Its Board of Directors

Bausch Health Companies Inc. Appoints John S. Barresi as the Company’s Senior Vice President, Controller and Chief Accounting Officer

Bausch Health Companies Inc. Provides Revenue Guidance for the Year Full Year 2022

Bausch Health Companies Inc. Announces Management Changes

Bausch Health Companies Inc. to Report Q1, 2022 Results on May 10, 2022

Bausch Health Companies Inc., Annual General Meeting, Jun 14, 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Bausch Health Companies Inc. Provides Earnings Guidance for the Year 2022

Bausch Health, Canada Announces Availability through Pharmacies Across Canada of its New Prescription Treatment TRULANCE

Bausch Health Companies Inc. to Report Q4, 2021 Results on Feb 23, 2022

Bausch Health Companies Inc. has filed an IPO.

Bausch Health Companies Inc. Announces New Post-Hoc Analysis of Pooled Results on the Safety and Efficacy of A Single Dose of Relistor Injection